Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Mitsubishi Tanabe’s Oral Edaravone Accepted for FDA Review in ALS
Mitsubishi Tanabe Pharma said on January 13 that an oral suspension version of its ALS therapy Radicava (edaravone) has been accepted by the US FDA for review, with a target date set for May 12 under the priority review pathway.…
To read the full story
Related Article
- US FDA Grants Orphan Exclusivity for ALS Drug Radicava ORS
April 10, 2024
- Oral Radicava Approved in Switzerland: Mitsubishi Tanabe
May 12, 2023
- Canada Approves Mitsubishi Tanabe’s Oral Edaravone for ALS
November 10, 2022
- US FDA OKs Mitsubishi Tanabe’s Oral Edaravone for ALS
May 16, 2022
- Mitsubishi Tanabe’s Oral Edaravone Accepted for Swiss Review in ALS
April 26, 2022
- Mitsubishi Tanabe Eyes US Submission of Oral Edaravone by March-End
December 13, 2021
BUSINESS
- Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
- Otsuka’s Astex Inks Breast Cancer R&D Pact with Genentech
July 7, 2026
- Keytruda’s No. 1 Streak Reaches 33 Months: Encise
July 7, 2026
- Takeda Rolls Out Higher-Concentration Kenketu Glovenin-I 10%
July 7, 2026
- Tanabe to Sell Manufacturing Unit to Towa, Transfer 17 Products
July 6, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…